설명

The global induced pluripotent stem cells market is poised to grow by US$ 1.9 10억 동안 2022-2028, CAGR로 진행 중 8.6% 예측 기간 동안, 데이터 및 분석 회사 StrategyHelix에 따르면.

이 보고서는 기간 동안 최신 시장 규모 데이터를 제공합니다. 2018-2021 그리고 예측 2028 covering key market aspects like sales value for induced pluripotent stem cells. The global induced pluripotent stem cells market is segmented on the basis of function, reprogramming method, method, 애플리케이션, 및 지역. By function, the global induced pluripotent stem cells market has been segmented into cell analysis, cell culture, cell differentiation, cellular and molecular bioengineering, cellular reprogramming. ~ 안에 2021, the cell differentiation segment made up the largest share of revenue generated by the induced pluripotent stem cells market. Based upon reprogramming method, the global induced pluripotent stem cells market is categorized into integrated, non-integrated. The non-integrated segment was the largest contributor to the global induced pluripotent stem cells market in 2021. On the basis of method, the global induced pluripotent stem cells market has been segmented into DNA-based, protein-based, RNA-based, small molecule-based. The DNA-based segment is estimated to account for the largest share of the global induced pluripotent stem cells market. 신청으로, the global induced pluripotent stem cells market has been segmented into academic research, 약물 개발, regenerative medicine. The drug development segment held the largest share of the global induced pluripotent stem cells market in 2021 예측 기간 동안 점유율을 유지할 것으로 예상됩니다.. 지리적으로, the global induced pluripotent stem cells market is segmented into Asia Pacific, 유럽, 미국, 세계의 나머지 (열).

The global induced pluripotent stem cells market is highly competitive. The report also includes the profiles of leading companies such as Bio-Techne Corporation, BlueRock Therapeutics LP, Bristol Myers Squibb (BMS), Cell Signaling Technology Inc., 코닝 법인, FUJIFILM Cellular Dynamics Inc., InvivoGen Limited, Lonza Group AG, Merck KGaA, Promega Corporation, Qiagen N.V., STEMCELL Technologies Inc., 써모 피셔 사이언티픽(주).

이 보고서는 이 업계에서 활동하는 회사 및 조직에 매우 귀중한 리소스입니다.. It provides a cohesive picture of the induced pluripotent stem cells market to help drive informed decision making for industry executives, 정책 입안자, 학생, 및 분석가.

보고 범위

Function: cell analysis, cell culture, cell differentiation, cellular and molecular bioengineering, cellular reprogramming
Reprogramming method: integrated, non-integrated
Method: DNA-based, protein-based, RNA-based, small molecule-based
애플리케이션: academic research, 약물 개발, regenerative medicine
지역: 아시아 태평양, 유럽, 미국, 세계의 나머지 (열)
년 고려: 이 보고서는 기간을 다룹니다 2018 에게 2028

이해관계자를 위한 주요 이점

– Get a comprehensive picture of the global induced pluripotent stem cells market
– 성장 분야 및 투자 동향 파악

목차

부분 1. 소개
– 연구 범위
– 공부 기간
– 지리적 범위
– 연구 방법론
부분 2. Induced pluripotent stem cells market overview
부분 3. Market breakdown by function
– Cell analysis
– Cell culture
– Cell differentiation
– Cellular and molecular bioengineering
– Cellular reprogramming
부분 4. Market breakdown by reprogramming method
– Integrated
– Non-integrated
부분 5. Market breakdown by method
– DNA-based
– Protein-based
– RNA-based
– Small molecule-based
부분 6. 애플리케이션별 시장 분석
– Academic research
– Drug development
– Regenerative medicine
부분 7. 지역별 시장 분석
– 아시아 태평양
– 유럽
– 미국
– 세계의 나머지 (열)
부분 8. 주요 기업
– Bio-Techne Corporation
– BlueRock Therapeutics LP
– Bristol Myers Squibb (BMS)
– Cell Signaling Technology, 주식회사.
– 코닝 법인
– FUJIFILM Cellular Dynamics, 주식회사.
– InvivoGen Limited
– Lonza Group AG
– Merck KGaA
– Promega Corporation
– Qiagen N.V.
– STEMCELL Technologies Inc.
– 써모 피셔 사이언티픽(주).
스트래티지헬릭스 소개
부인 성명